Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4640
Peer-review started: November 16, 2021
First decision: December 27, 2021
Revised: January 9, 2022
Accepted: April 3, 2022
Article in press: April 3, 2022
Published online: May 16, 2022
The contradictory process of coagulation and anticoagulation maintains normal physiological function, and platelets (PLTs) play a key role in hemostasis and bleeding. When severe thrombocytopenia and deep vein thrombosis (DVT) occur simultaneously, the physician will be confronted with a great challenge, especially when interventional thrombectomy fails.
We describe a 52-year-old woman who suffered from myelodysplastic syndrome with severe thrombocytopenia and protein S deficiency with right lower extremity DVT. In this patient, the treatment of DVT was associated with numerous contradictions due to severe thrombocytopenia, especially when interventional thrombectomy was not successful. Fortunately, fondaparinux sodium effectively alleviated the thrombus status of the patient and gradually decreased the D-dimer level. In addition, no increase in bleeding was noted. The application of eltro
This is a contradictory and complex case, and fondaparinux sodium and eltrombopag may represent a good choice for the treatment of DVT in patients with severe thrombocytopenia.
Core Tip: One 52-year-old Chinese female suffered from myelodysplastic syndrome of multilineage dysplasia with severe thrombocytopenia and thrombophilia with deep vein thrombosis. In the basic treatment for underlying diseases, the treatment of thrombosis is full of contradictions because of the low platelets, especially in the situation that the curative effect of surgical thrombectomy was not obvious. Pleasantly, Fondaparinux sodium effectively alleviated the thrombus status, and the D-dimer gradually decreased. In addition, there was not any unexpected bleeding. This patient’s circumference of right lower limb recovered and restored the movement basically finally.